NASDAQ:VRAY ViewRay - VRAY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ViewRay, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.36 0.00 (0.00%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.30▼$3.3850-Day Range$3.35▼$4.8152-Week Range$2.39▼$4.96Volume792,670 shsAverage Volume1.37 million shsMarket Capitalization$610.85 millionP/E RatioN/ADividend YieldN/APrice Target$6.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ViewRay MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside100.9% Upside$6.75 Price TargetShort InterestBearish4.79% of Shares Sold ShortDividend StrengthN/ASustainability-0.49Upright™ Environmental ScoreNews Sentiment0.08Based on 3 Articles This WeekInsider TradingSelling Shares$173,460 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.60) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector426th out of 1,005 stocksElectromedical Equipment Industry7th out of 24 stocks 3.4 Analyst's Opinion Consensus RatingViewRay has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.75, ViewRay has a forecasted upside of 100.9% from its current price of $3.36.Amount of Analyst CoverageViewRay has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.79% of the outstanding shares of ViewRay have been sold short.Short Interest Ratio / Days to CoverViewRay has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in ViewRay has recently increased by 1.52%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldViewRay does not currently pay a dividend.Dividend GrowthViewRay does not have a long track record of dividend growth. Previous Next 5.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreViewRay has received a 82.75% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "MRI machines", "Radiation therapy machines", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for ViewRay is -0.49. Previous Next 1.7 News and Social Media Coverage News SentimentViewRay has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ViewRay this week, compared to 2 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ViewRay insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $173,460.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of ViewRay is held by insiders.Percentage Held by Institutions84.40% of the stock of ViewRay is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ViewRay are expected to grow in the coming year, from ($0.60) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ViewRay is -5.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ViewRay is -5.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViewRay has a P/B Ratio of 7.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ViewRay (NASDAQ:VRAY) StockViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.Read More Receive VRAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter. Email Address VRAY Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comJames F. Dempsey Sells 42,000 Shares of ViewRay, Inc. (NASDAQ:VRAY) StockMarch 18, 2023 | americanbankingnews.comStockNews.com Begins Coverage on ViewRay (NASDAQ:VRAY)March 26, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 11, 2023 | finance.yahoo.comViewRay, Inc. (NASDAQ:VRAY) Q4 2022 Earnings Call TranscriptMarch 7, 2023 | finance.yahoo.comMilitary University Hospital Prague Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Treat Cancer PatientsMarch 3, 2023 | msn.comViewRay Earnings Perspective: Return On Capital EmployedMarch 1, 2023 | finance.yahoo.comViewRay Full Year 2022 Earnings: EPS Beats ExpectationsJanuary 31, 2023 | finance.yahoo.comViewRay Announces Conference Call for Fourth Quarter 2022 Financial Results to be Held After Market on February 27, 2023March 26, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. January 12, 2023 | finance.yahoo.comFindings Published in JAMA Oncology Demonstrate Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate CancerJanuary 9, 2023 | finance.yahoo.comViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial OfficerJanuary 5, 2023 | finance.yahoo.comChindex Medical Acquires 10 ViewRay MRIdian® Systems for Advanced Cancer TreatmentDecember 27, 2022 | finance.yahoo.comWith 63% ownership, ViewRay, Inc. (NASDAQ:VRAY) boasts of strong institutional backingNovember 30, 2022 | finance.yahoo.comSusan Schnabel Just Bought 33% More Shares In ViewRay, Inc. (NASDAQ:VRAY)November 24, 2022 | seekingalpha.comViewRay: Revise Thesis To Buy, Multiple Upside Targets In PlaceNovember 15, 2022 | finance.yahoo.comViewRay Expands Access to Non-Dilutive Capital With New Debt FacilityNovember 14, 2022 | finance.yahoo.comViewRay® to Participate in the 34th Annual Piper Sandler Healthcare ConferenceOctober 27, 2022 | finance.yahoo.comMIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate CancerOctober 25, 2022 | reuters.comVRAY.OQ - Viewray Inc | Stock Price & Latest News | ReutersOctober 24, 2022 | finance.yahoo.comViewRay Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer PatientsOctober 19, 2022 | finance.yahoo.comMRIdian Clinical Studies and Initial MRIdian A3i Clinical Experience to be Highlighted at ASTRO 2022October 18, 2022 | finance.yahoo.comViewRay Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation TherapyOctober 16, 2022 | finance.yahoo.comViewRay Announces Conference Call for Third Quarter 2022 Financial Results to be Held After Market on November 1, 2022 - Yahoo FinanceOctober 4, 2022 | finance.yahoo.comSan Pietro Fatebenefratelli Hospital Treats its 1,000th Patient with MRIdian® MRI-Guided Radiation TherapyOctober 3, 2022 | benzinga.comViewRay to host Investor Day - ViewRay (NASDAQ:VRAY) - BenzingaOctober 3, 2022 | finance.yahoo.comViewRay to host Investor DaySeptember 30, 2022 | businesswire.comInsights on the Radiation Oncology Global Market to 2027 - Rapid Expansion of Cancer Research Centers Worldwide is Positively Influencing Growth - ResearchAndMarkets.com - Business WireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VRAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter. Email Address VRAY Company Calendar Last Earnings2/27/2023Today3/26/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRAY CUSIPN/A CIK1597313 Webwww.viewray.com Phone(440) 703-3210Fax800-417-3459Employees267Year Founded2004Price Target and Rating Average Stock Price Forecast$6.75 High Stock Price Forecast$8.00 Low Stock Price Forecast$5.50 Forecasted Upside/Downside+100.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-107,330,000.00 Net Margins-105.01% Pretax Margin-105.01% Return on Equity-93.57% Return on Assets-38.79% Debt Debt-to-Equity Ratio0.95 Current Ratio2.36 Quick Ratio2.04 Sales & Book Value Annual Sales$102.21 million Price / Sales5.98 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book7.47Miscellaneous Outstanding Shares181,800,000Free Float177,260,000Market Cap$610.85 million OptionableOptionable Beta1.00 Social Links Key ExecutivesScott William DrakePresident, Chief Executive Officer & DirectorDrew HillSenior Vice President-Operations & DevelopmentWilliam Patrick BurkeChief Financial Officer & Executive Vice PresidentJames F. DempseyChief Scientific OfficerMartin FussChief Medical OfficerKey CompetitorsZynexNASDAQ:ZYXIEdap TmsNASDAQ:EDAPAxoGenNASDAQ:AXGNBioLife SolutionsNASDAQ:BLFSOutset MedicalNASDAQ:OMView All CompetitorsInsiders & InstitutionsJames F DempseySold 42,000 sharesTotal: $173,460.00 ($4.13/share)Parallax Volatility Advisers L.P.Bought 258,180 shares on 2/27/2023Ownership: 0.142%Macquarie Group Ltd.Sold 70,175 shares on 2/21/2023Ownership: 0.124%State of WyomingBought 12,632 shares on 2/16/2023Ownership: 0.007%Kahn Brothers Group Inc.Sold 30,000 shares on 2/15/2023Ownership: 0.895%View All Insider TransactionsView All Institutional Transactions VRAY Stock - Frequently Asked Questions Should I buy or sell ViewRay stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRAY shares. View VRAY analyst ratings or view top-rated stocks. What is ViewRay's stock price forecast for 2023? 5 analysts have issued twelve-month price objectives for ViewRay's stock. Their VRAY share price forecasts range from $5.50 to $8.00. On average, they anticipate the company's share price to reach $6.75 in the next year. This suggests a possible upside of 100.9% from the stock's current price. View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts. How have VRAY shares performed in 2023? ViewRay's stock was trading at $4.48 on January 1st, 2023. Since then, VRAY shares have decreased by 25.0% and is now trading at $3.36. View the best growth stocks for 2023 here. When is ViewRay's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our VRAY earnings forecast. How were ViewRay's earnings last quarter? ViewRay, Inc. (NASDAQ:VRAY) announced its earnings results on Monday, February, 27th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. The firm earned $34.70 million during the quarter, compared to analyst estimates of $34.65 million. ViewRay had a negative trailing twelve-month return on equity of 93.57% and a negative net margin of 105.01%. The company's revenue was up 70.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.16) earnings per share. What ETFs hold ViewRay's stock? ETFs with the largest weight of ViewRay (NASDAQ:VRAY) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC) and iShares U.S. Medical Devices ETF (IHI) and What guidance has ViewRay issued on next quarter's earnings? ViewRay updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $127.76 million-$143.09 million, compared to the consensus revenue estimate of $136.01 million. What is Scott Drake's approval rating as ViewRay's CEO? 5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ViewRay own? Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB). When did ViewRay IPO? (VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers. What is ViewRay's stock symbol? ViewRay trades on the NASDAQ under the ticker symbol "VRAY." Who are ViewRay's major shareholders? ViewRay's stock is owned by many different institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (9.19%), Neuberger Berman Group LLC (5.44%), Group One Trading L.P. (0.00%), Susquehanna International Group LLP (0.00%), Geode Capital Management LLC (1.50%) and Silverarc Capital Management LLC (1.33%). Insiders that own company stock include Brian K Roberts, Caley Castelein, Influence Ltd Strong, International Ltd Fosun, James F Dempsey, Scott William Drake, Susan C Schnabel and Zachary William Stassen. View institutional ownership trends. How do I buy shares of ViewRay? Shares of VRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ViewRay's stock price today? One share of VRAY stock can currently be purchased for approximately $3.36. How much money does ViewRay make? ViewRay (NASDAQ:VRAY) has a market capitalization of $610.85 million and generates $102.21 million in revenue each year. The company earns $-107,330,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. How many employees does ViewRay have? The company employs 267 workers across the globe. Does ViewRay have any subsidiaries? The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc..Read More How can I contact ViewRay? ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The official website for the company is www.viewray.com. The company can be reached via phone at (440) 703-3210, via email at investors@viewray.com, or via fax at 800-417-3459. This page (NASDAQ:VRAY) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.